PURCHASE AGREEMENT between LIGAND PHARMACEUTICALS INCORPORATED and KING PHARMACEUTICALS, INC. and KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. Dated as of September 6, 2006Purchase Agreement • September 12th, 2006 • King Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS PURCHASE AGREEMENT (this “Agreement”), dated as of September 6, 2006 (the “Execution Date”), is entered into by and between Ligand Pharmaceuticals Incorporated, a Delaware corporation, and all of its successors and assigns (“Seller”), King Pharmaceuticals, Inc., a Tennessee corporation (“King”), and King Pharmaceuticals Research and Development, Inc., a Delaware corporation and wholly owned subsidiary of King (“King R&D”, and together with King, “Purchaser”). Each of Seller and Purchaser is sometimes referred to herein, individually, as a “Party” and, collectively, as the “Parties.” All capitalized terms used herein shall have the meanings specified in Article I below or elsewhere in this Agreement, as applicable.
